Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children

Anti-Cancer Drugs

Volumn 11, Issue 4, 2000, Pages 237-241

  Eksborg, Staffan ^a   Söderhäll, Stefan ^a   Frostvik Stolt, Marianne ^a   Lindberg, Annika ^a   Liliemark, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Children; Dosing; Down's syndrome; Etoposide; Pharmacokinetics; VP 16

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOWN SYNDROME; FEMALE; HUMAN; INFANT; MALE; PHARMACOKINETICS; PLASMA HALF LIFE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; ETOPOSIDE; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE;

EID: 0034047865     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200004000-00002     Document Type: Article

References (24)

1. 1. Miller RW. Neoplasia and Down's syndrome. Ann NY Acad Sci 1970; 171: 637-44.
2. 2. Rowley JD. Down syndrome and acute leukaemia: increased risk may be due to trisomy 21. Lancet 1981; ii: 1020-2.
3. 3. Robison LL, Nesbit Jr ME , Sather HN, et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group. J Pediatr 1984; 105: 235-42.
4. 4. Liliemark E, Pettersson B, Peterson C, Liliemark J. High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukaemic cells. J Chromatogr B Biomed Appl 1995; 669: 311-7.
5. 5. Dunne A. JANA: a new iterative polyexponential curve stripping program. Comput Methods Programs Biomed 1985; 20: 269-75.
6. 6. Statistical Consultants Inc. PC-NONLIN and NONLIN 84: Software for the statistical analysis of nonlinear models. Am Statistican 1986; 40: 52.
7. 7. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 1974; 2: 123-48.
8. 8. Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 1993; 32: 411-8.
9. 9. Reilly JJ, Workman P. Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol 1994; 34: 3-13.
10. 10. Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 1994; 56: 503-11.
11. 11. Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 2390-7.
12. 12. D'Incalci M, Farina P, Sessa C, et al. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 1982; 7: 141-5.
13. 13. Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 1982; 7: 147-50.
14. 14. Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans W. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 1984; 44: 3109-13.
15. 15. Lowis SP, Pearson AD, Newell DR, Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 1993; 53: 4881-9.
16. 16. Boos J, Krumpelmann S, Schulze-Westhoff P, Euting T, Berthold F, Jurgens H. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol 1995; 13: 2954-60.
17. 17. Lowis SP, Price L, Pearson AD, Newell DR, Cole M. A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. Br J Cancer 1998; 77: 2318-23.
18. 18. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223-52.
19. 19. Kaul S, Srinivas NR, Mummaneni V, Igwemezie LN, Barbhaiya RH. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients. Semin Oncol 1996; 23: 23-9.
20. 20. Stowe CD, Phelps SJ. Altered clearance of theophylline in children with Down syndrome: a case series. J Clin Pharmacol 1999; 39: 359-65.
21. 21. Blatt J, Albo V, Prin W, Orlando S, Wollman M. Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia [letter]. Lancet 1986; ii: 914.
22. 22. Garré ML, Relling MV, Kalwinsky D et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987; 111: 606-12.
23. 23. Peeters M, Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr 1987; 146: 416-22.
24. 24. Dördelmann M, Schrappe M, Reiter A et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998; 12: 645-51.